Indeed, AR-negative prostate cancer cells have been shown to respond to AURKA [30], FGFR, or MAPK inhibitors [11], in line with the notion that these pathways are activated as a result of the lineage switch. This evidence concerns the gene AURKA and Familial prostate cancer.